Gadoteridol

CAS No.	120066-54-8	Cat. No.	BCP13402
Name	Gadoteridol
Synonyms	SQ-32692; SQ 32692; SQ32692; Gd-HP-DO3A; GD-HP-DO 3A;Gd-HPDO3A;Gd-hydroxypropyl-D03A;
Formula	C17H29GdN4O7	M. Wt	558.68

Description	Gadoteridol provides contrast enhancement of the brain, spine and surrounding tissues resulting in improved visualization (compared with unenhanced MRI) of lesions with abnormal vascularity or those thought to cause a disruption of the normal blood brain barrier. Gadoteridol can also be used for whole body contrast enhanced MRI including the head, neck, liver, breast, musculoskeletal system and soft tissue pathologies. n MRI, visualization of normal and pathological brain tissue depends in part on variations in the radiofrequency signal intensity that occur with changes in proton density, alteration of the T1, and variation in T2. When placed in a magnetic field, gadoteridol shortens the T1 relaxation time in tissues where it accumulates. Abnormal vascularity or disruption of the blood-brain barrier allows accumulation of gadoteridol in lesions such as neoplasms, abscesses, and subacute infarcts.
Pathways	Others Pathway
Targets	Others

Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.

For product details of different batches, please contact our Customer

Products are for research use only and not for human use. We do not sell to patients.